---

What Is Cardiomyopathy?

Cardiomyopathy is a disease of the heart muscle that makes it harder for the heart to pump blood to the rest of the body. It is a leading cause of heart failure and sudden cardiac death, and it is a common reason for heart transplant. Cardiomyopathy can affect people of all ages — including children and young adults — and is often inherited. With proper diagnosis and individualized management, many patients live full, active lives.

Types of Cardiomyopathy

Dilated Cardiomyopathy (DCM) — The most common type. The heart’s main pumping chamber (left ventricle) becomes enlarged and weakened, reducing its ability to pump effectively. Causes include viral infection, alcohol use, genetic mutations, chemotherapy, and idiopathic (unknown) causes. DCM is a major cause of heart failure with reduced ejection fraction (HFrEF).

Hypertrophic Cardiomyopathy (HCM) — The heart muscle becomes abnormally thickened (hypertrophied), making it harder for the heart to pump and potentially obstructing blood flow out of the left ventricle. HCM is the most common genetic cardiovascular disease and a leading cause of sudden cardiac death in young athletes. Symptoms include shortness of breath, chest pain, palpitations, and exertional syncope.

Restrictive Cardiomyopathy — The heart muscle becomes stiff and less flexible, impairing its ability to fill with blood. Causes include amyloidosis, sarcoidosis, hemochromatosis, and radiation therapy.

Arrhythmogenic Cardiomyopathy (ARVC) — A genetic disease in which heart muscle is replaced by fatty or fibrous tissue, primarily in the right ventricle. It is associated with ventricular arrhythmias and sudden cardiac death, particularly in young athletes.

---

Diagnosis and Evaluation

Diagnosis of cardiomyopathy requires echocardiography to assess heart size, wall thickness, and ejection fraction — the key measure of pumping function. Cardiac MRI provides superior tissue characterization and is often essential in diagnosing HCM, ARVC, and infiltrative cardiomyopathies. Genetic testing is recommended for patients with HCM and their first-degree relatives, as HCM is inherited in an autosomal dominant pattern. Holter monitoring evaluates for ventricular arrhythmias that may warrant an implantable defibrillator (ICD). In selected patients, a cardiac catheterization or endomyocardial biopsy may be performed.

Treatment Approach

Treatment is individualized based on cardiomyopathy type, severity, symptoms, and genetic profile. For dilated cardiomyopathy, evidence-based heart failure medications — including ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — are the cornerstone of therapy. Cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICD) are used for selected patients. Hypertrophic cardiomyopathy is managed with beta-blockers or calcium channel blockers, mavacamten (a novel cardiac myosin inhibitor), and septal reduction therapy for obstructive HCM with severe symptoms. Activity restriction and ICD implantation may be recommended for high-risk HCM patients.

---

Why Choose Cross County Cardiology?

• Board-Certified, FACC Cardiologists — Fellowship of the American College of Cardiology credentialed physicians
• Affiliated with Mount Sinai & Hackensack Meridian Health — Academic medical center connectivity for complex referrals
• 5 NJ Locations — Secaucus, Edgewater, Teaneck, Hoboken, and North Bergen
• Same-Week Appointments Available — Fast access without long waits
• Comprehensive In-Office Diagnostics — Echocardiography, stress testing, Holter monitoring, and vascular studies on-site

---

Frequently Asked Questions

Is cardiomyopathy hereditary?

Several types of cardiomyopathy are strongly genetic. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease, affecting approximately 1 in 500 adults. Dilated cardiomyopathy has a genetic basis in about 30–40% of cases. If you are diagnosed with cardiomyopathy, genetic testing and screening of first-degree family members is often recommended.

Can cardiomyopathy be reversed?

Some forms of cardiomyopathy are reversible if the underlying cause is identified and treated. Peripartum cardiomyopathy (related to pregnancy) and alcohol-induced cardiomyopathy often improve significantly with appropriate management. Dilated cardiomyopathy from other causes may partially or fully recover with optimal medical therapy. Hypertrophic and restrictive cardiomyopathies are generally not reversible but can be effectively managed.

Can athletes develop cardiomyopathy?

Yes. Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young athletes. All competitive athletes should be screened with a history, physical examination, and EKG. An echocardiogram is often performed if the initial screening raises concern. Athletes with known HCM require specialized evaluation to determine eligibility for competitive sports.

What is ejection fraction?

Ejection fraction (EF) is a measure of how much blood the left ventricle pumps out with each contraction, expressed as a percentage. A normal EF is 55–70%. An EF below 40% indicates significant weakness of the heart muscle (heart failure with reduced ejection fraction, or HFrEF). EF is measured by echocardiogram and is a key number in guiding cardiomyopathy treatment.

What medications are used for cardiomyopathy?

For dilated cardiomyopathy and HFrEF, guideline-directed medical therapy includes ACE inhibitors or ARNIs (sacubitril/valsartan), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — the four pillars of modern heart failure therapy. For hypertrophic cardiomyopathy, beta-blockers, calcium channel blockers, and the novel myosin inhibitor mavacamten are used. Diuretics manage fluid retention and breathlessness.